Table 1.

Summary of complete response cases with nivolumab treatment for Stage IV gastric cancer

References	Year	Age	Sex	Initial treatment	Metastasis (recurrence)	Number of chemotherapy regimens prior to nivolumab	Course of nivolumab	Post-nivolumab surgery	Post nivolumab chemotherapy	Adverse events	Prognosis
Dai et al. [13]	2022	66	M	Palliative surgery	Liver	1	8	Hepatectomy	None	Immune pneumonia	32 months
Toyota et al. [14]	2022	73	M	Chemotherapy	Liver (invasion)	None	5	Distal gastrectomy and hepatectomy	S-1	None	N/A
Pan et al. [15]	2022	45	M	Chemotherapy	Liver, lung, lymph nodes	3	5	Total gastrectomy	Nivolumab	Exfoliative dermatitis eruption	4 years
Takami et al. [16]	2021	70	F	Total gastrectomy	Peritoneal dissemination, lymph nodes	2	54	None	Nivolumab	None	7 years
Watanabe et al. [17]	2021	73	M	Chemotherapy	Liver	2	31	Total gastrectomy	None	None	43 months
Kumamoto et al. [18]	2021	69	M	Chemotherapy	Lymph nodes	2	8	Esophagectomy	None	None	Over 12 months
Komo et al. [19]	2021	69	F	Chemotherapy	Peritoneal dissemination	2	9	None	None	Immune pneumonia	Over 20 months
Matsumoto et al. [9]	2020	63	F	Chemotherapy	Liver, lung	2	26	Distal gastrectomy	Nivolumab	None	41 months
Kuhara et al. [20]	2020	60	F	Chemotherapy	Lymph nodes	2	39	None	Nivolumab	Rash	Over 48 months
Toyota et al. [21]	2020	75	M	Chemotherapy	Peritoneal dissemination	2	23	Distal gastrectomy	None	None	Over 20 months
Toyota et al. [22]	2020	70	M	Chemotherapy	Pancreas and spleen (invasion), lymph nodes	2	24	Total gastrectomy with distal pancreatosplenectomy	None	Rash, gland hypofunction	Over 20 months
Kashima et al. [23]	2019	25	M	Chemotherapy	Lymph nodes	1	48	Total gastrectomy	Nivolumab	None	Over 60 months
Namikawa et al. [24]	2018	77	M	Total gastrectomy	Spleen, liver	2	16	None	Nivolumab	None	28 months

N/A: not available